Indication: Overactive Bladder

A Randomized, Double-Blind, Parallel-Group, Placebo- and Active- Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder.

Year: 2013
Type: Pharmaceutical - Other
Phase: III
Indication: Overactive Bladder

A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive Bladder.

Year: 2013
Type: Pharmaceutical - Other
Phase: III
Indication: Overactive Bladder

CONNECT WITH US

CONTACT US

Disclaimer: This website provides general information only; it should not be construed as medical advice nor does it replace the need to seek medical advice from a qualified medical professional. To the maximum extent permitted by law, Genesis Research Services Pty Ltd will not be liable in any way for any injury, loss or damage suffered by you through accessing or using the information on this website. View our Privacy Policy. You are strictly prohibited from downloading, copying, altering, modifying, distributing, adapting, modifying and/or re-transmitting any or all of the content on the website for any commercial use without the written consent of Genesis Research Services.